Compared with conventional fibrates, pemafibrate is considered to have a lower risk of rhabdomyolysis and renal dysfunction, probably because it is a selective PPARα modulator of hepatic lipid metabolism and is excreted by the liver. Here, PPARA is linked to rhabdomyolysis.